SLCO1B1 and myopathy: More importantly, the results of our study may serve as evidence for guiding the preemptive SLCO1B1 testing by identifying individuals with high risk of simvastatin-related myopathy and thereby optimizing the statin therapy to avoid drug-related myopathy and promote a stronger adherence.